INTRODUCTION
Deficiencies of specific lysosomal hydrolases in lysosomal storage disorders (LSDs) cause accumulation of their undegraded target substrates. However, it is not clear if these substrates themselves are the primary mediators of toxicity. Indeed, the biological pathways from lysosomal enzyme deficiency to cellular dysfunction are still largely unknown (1, 2) . Interestingly, despite the great structural diversity of the accumulating substrates in the different LSDs, these disorders share many phenotypic similarities, suggesting the presence of common pathogenetic mechanisms. Many LSDs are associated with progressive and severe neurodegeneration which represents the most difficult challenge for their therapy (2) . In previous studies, we detected severe neurodegeneration in murine models of mucopolysaccharidoses type II and IIIA (MPSII and MPSIIIA, respectively) and of multiple sulfatase deficiency (MSD) (3 -6) .
The degradation of intracellular proteins is performed by two major mechanisms: the ubiquitin-proteasome system (UPS) and macroautophagy (hereafter referred to as autophagy). The latter is a lysosomal-dependent catabolic pathway through which long-lived cytosolic proteins and organelles, such as mitochondria, are sequestered by double membrane vesicles (autophagosomes) and ultimately degraded after autophagosome-lysosome fusion (7) . Many of the aggregateprone proteins causing late-onset neurodegenerative conditions, such as Huntington's and familial forms of Parkinson's diseases, are autophagy substrates (8) . In addition, knock-out of autophagy genes causes abnormal protein accumulation in ubiquitinated inclusions and neurodegeneration in mice (9, 10) .
We hypothesized that LSDs are associated with a lysosomal dysfunction that impairs the autophagic pathway ultimately leading to cell death. To test this hypothesis, we studied the mouse models of two LSDs: MSD, which is caused by the deficiency of the sulfatase modifying factor 1 (SUMF1) gene involved in the post-translational modification of sulfatases (6, 11, 12) , and MPS-IIIA, caused by sulfamidase deficiency (13) . Our results revealed a block of autophagic pathway occurs as a consequence of decreased ability of lysosomes to fuse with autophagosomes. This results in the cellular accumulation of toxic substrates which are the putative mediators of cell death.
RESULTS

Increased autophagosome number in MSD
We assessed autophagosome number in brain sections from MSD mice by using an antibody detecting the autophagosome marker LC3 (14) . During autophagosome formation, the LC3-I isoform is converted into LC3-II, whose amount (compared to actin or tubulin) correlates with the number of autophagosomes (14) . LC3-II is the only known protein that specifically associates with autophagosomes and not with other vesicular structures. LC3-II levels were clearly raised in whole brain homogenates from MSD mice, compared to wild-type littermates at 1, 3 and 6 months of age (Fig. 1A) . Furthermore, immuno-fluorescence analysis revealed increased numbers of LC3-positive vesicles in the cerebral cortex, cerebellum and thalamus of MSD mice, compared to corresponding brain regions of wild-type mice (Fig. 1B) . Electron microscopy evaluation of cerebellum ( Fig. 1C and D) and cerebral cortex ( Fig. 1E and F) sections from MSD mice showed abnormally abundant autophagosomes. Interestingly, the morphology of autophagic vacuoles accumulating in MSD mice resembled that of early immature autophagosomes (15, 16) (Fig. 1C-F) , suggesting the presence of a defective maturation.
A similar increase in LC3-II levels was observed in mouse embryonic fibroblasts (MEFs) and embryonic liver macrophages (ELMs) ( Fig. 2A )-macrophages were previously identified as the primary site of lysosomal storage in MSD mice (6) . The increase in both number and size of autophagosomes was confirmed in MEFs by quantitative analysis (Fig. 2B and C) .
Autophagosome-lysosome fusion is impaired in MSD
Clearance of autophagosomes occurs via fusion with lysosomes. We postulated that accumulation of autophagosomes in MSD is due to defective clearance caused by impaired autophagosome-lysosome fusion. To test this hypothesis, we analyzed the subcellular localization of the lysosomal marker lgp120 (LAMP1) and the autophagosomal marker LC3 by confocal microscopy. These experiments demonstrated that the extent of lgp120/LC3 co-localization was significantly reduced (ranging from 40 to 50%) in MSD compared to wild-type MEFs, thus indicating impaired autophagosome-lysosome fusion ( Fig. 3A and B) . This was observed both in normal medium (basal autophagy) (Fig. 3A) and in starved cells (induced autophagy) (Fig. 3B) .
To characterize this impairment, we used drugs which either induce or inhibit autophagy. Autophagy stimulation with rapamycin increased LC3-II levels in both MSD and wild-type MEFs (Fig. 4) . Moreover, LC3-II levels in MSD MEFs were further increased with bafilomycin A1, an inhibitor autophagosome-lysosome fusion (17) , alone or in combination with rapamycin, suggesting that the block of autophagy is not complete (Fig. 4) .
Decreased ability of MSD cells to degrade exogenous aggregate-prone proteins
Defective autophagosome-lysosome fusion may lead to an impairment of autophagy. We investigated the ability of MSD cells to degrade aggregate-prone proteins which are autophagy substrates (18) . These include the mutant huntingtin and A53T a-synuclein which are involved in Huntington and familial Parkinson diseases, respectively. Mutant huntingtin exon 1 constructs aggregate readily in tissue culture and form inclusions readily visible by light microscopy. The proportion of cells with such inclusion is linearly related to the expression levels of the construct (19) . The A53T a-synuclein construct does not form overt inclusions in the cell lines we have studied (20) . We expressed these mutant proteins in MSD cells to test the functionality of the autophagic pathway. The Gln 74 ;Q74 huntingtin, which encodes the first exon of huntingtin with 74 glutamine repeats, and the A53T a-synuclein were fused to green fluorescent protein (GFP) and transiently expressed in both MEFs and ELMs derived from MSD mice. Forty-eight hours after transfection, cells were collected and GFP-fused proteins were detected by western blot. Figure 5A shows an increased accumulation of both types of mutant proteins in MSD compared to wild-type cells. In addition, immuno-fluorescence analysis revealed that the number of GFP-Q74 aggregates was also significantly higher in MSD MEFs and ELMs compared to wild-type cells ( Fig. 5B and C) . Notably, when cells were analyzed at earlier time points, no significant differences in the accumulation of GFP-Q74 were observed between wild-type and MSD cells (Supplementary Material), this indicating that only at later time points accumulation of overexpressed proteins occurs. Moreover, GFP alone did not accumulate in MSD cells (Supplementary Material) demonstrating that increased levels of GFP-Q74 and GFP-A53T are due to autophagic defective degradation and not to difference in transfection efficiency. Taken together, these data indicate a dysfunction of autophagy with consequent decreased ability of MSD cells to degrade aggregate-prone proteins.
Polyubiquitinated proteins progressively accumulate in MSD neurons
Autophagy is responsible for constitutive protein turnover (8) . This function appears to be particularly important in neuronal cells and is relevant to neurodegenerative diseases (21, 22) . Knockout of autophagy genes results in suppression of autophagy and accumulation of inclusion bodies, which contain polyubiquitinated proteins, in neurons (9,10). We detected a massive and progressive accumulation of ubiquitin-positive inclusions in the cerebral cortex as well as in other brain regions of MSD mice by both anti Ub immuno-histochemical and immuno-fluorescence analyses ( Fig. 6A and B and data not shown). Co-localization of Ubiquitin with NeuN neuronal marker indicates that 
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Human Molecular Genetics, 2008, Vol. 17, No. 1 ubiquitin inclusions are located in neurons (Fig. 6B ). Progressive accumulation of polyubiquitinated proteins was also detected by western blotting of brain homogenates (Fig. 6C) . Importantly, analysis of chymotrypsin-like proteasome activity in MSD brain at several ages revealed that proteasome function is not affected in MSD mice (data not shown), indicating that the accumulation of ubiquitinated proteins is due to defective autophagy rather than to UPS impairment. In addition, we found that P62/SQSTM1 significantly accumulates (Fig. 6D) , and co-localizes with ubiquitinpositive inclusions (Fig. 6E ) in brain from MSD mice. The p62/SQSTM1 protein is known to be a common component of ubiquitin-positive protein aggregates in neurodegenerative diseases (23) , being involved in the targeting of polyubiquitinated proteins to the autophagosomes and selectively degraded via the autophagic pathway (24) .
Accumulation of dysfunctional mitochondria in MSD mice
Autophagy also plays a crucial role in the degradation and turnover of cellular organelles like mitochondria. Indeed, it has been suggested that autophagy selectively degrades dysfunctional mitochondria (25) . Fragmented and dysfunctional mitochondria have been reported to accumulate in patients with mucolipidosis types II, III and IV and in patients with neuronal ceroid lipofuscinosis 2 (NCL2), suggesting that lysosomal storage in these diseases impairs autophagy-mediated mitochondrial turnover (26, 27) . Electron microscopy analysis revealed an increased number of mitochondria in MSD brain sections and MEFs ( Fig. 7A and B) . Consistently, an increase of Cox4 (a mitochondrial marker) levels was detected by western blotting in MSD brain samples (Fig. 7C) . To examine the function of accumulating mitochondria, we measured the mitochondrial membrane potential (DCm) in WT and MSD MEFs by using , a mitochondria-specific voltage dependent dye (DiOC 6 ). As shown in Fig. 7D , MSD MEFs show a significant reduction in the DCm compared to wild-type cells in both normal and starved conditions, thus indicating that mitochondria accumulating in MSD are dysfunctional.
Impairment of autophagy in MPSIIIA
Overall, our data identify an impairment of autophagy in MSD, leading to the accumulation of polyubiquitinated proteins and of dysfunctional mitochondria. To investigate whether this applies to other LSDs caused by defective hydrolases, we analyzed the autophagic pathway in the murine model of MPSIIIA, which is also associated with severe neurodegeneration (4, 5) . The results obtained in MPSIIIA mice were similar to those of MSD mice. We detected increased LC3II levels in MPSIIIA MEFs (Fig. 8A) as well as accumulation of autophagosomes in brain samples (Fig. 8B) . Consequently, accumulation of ubiquitin-positive inclusions (Fig. 8C ) and P62/SQSTM1 (Fig. 8D) were observed in the brain of MPSIIIA mice. In addition, electron microscopy analysis revealed an increased number of mitochondria in 
DISCUSSION
Mucopolysaccharidoses represent a substantial proportion (25%) of all LSDs (28). Our results in MSD and MPSIIIA indicate that lysosomal storage in these diseases causes cellular dysfunction by blocking autophagic protein clearance. We provide evidence for this block at both structural (i.e. defective autophagosome-lysosome fusion) and functional levels (i.e. impaired ability of cells to degrade exogenous aggregateprone proteins, and accumulation of endogenous substrates, such as ubiquitinated proteins, P62 and mitochondria). Accumulation of ubiquitinated proteins was also observed in mice with autophagy gene knockouts and likely results from increased ubiquitination of substrates by virtue of their longer half-lives. These mice show severe neurodegeneration, suggesting that neurons, compared to other cell types, are more susceptible to a block of autophagy. This may be because non-mitotic cells cannot dilute accumulating cytosolic contents by cell division. This may also explain the prevalence of a neurological phenotype in LSDs.
Furthermore, our data provide an explanation for previous reports of autophagosome accumulation in other types of LSDs, namely Danon disease (15), NCL2 (26, 29) , Glycogenosis type II (Pompe disease) (30) and Mucolipidosis IV (27) . Note that these previous studies did not resolve the crucial issue if the autophagosome accumulation was due to increased formation of autophagosomes (which would lead to increased degradation of autophagic substrates), or decreased autophagosome-lysosome fusion (which results in decreased degradation of such substrates). Clearly, these different scenarios result in vastly different pathological consequences. An induction, rather than a block, of autophagy was observed in NPC types 1 and 2, associated with increased levels of beclin-1 expression (31,32). However, NPC represents the 'atypical' type of LSD as it is caused by mutations in cholesterol transporters, thus suggesting a direct role of lipid trafficking in the regulation of autophagy (32) . Accordingly, we found no differences in beclin-1 expression between tissues from MSD mice and wild-type littermates (data not shown). We propose a model which identifies a block of autophagy as a crucial component in the pathogenesis of LSDs (Fig. 9) . According to this model, lysosomal accumulation of undegraded substrates results in defective fusion between autophagosomes and lysosomes and causes a block of the autophagic pathway. As a consequence of this block, toxic proteins and dysfuctional mitochondria accumulate, ultimately leading to apoptosis, either directly or through the induction of chronic inflammation and cytokine release (6) . Indeed, cells with impaired autophagy have an increased susceptibility to mitochondria-mediated apoptosis (33, 34) . It is interesting to note that bafilomycin A1, a proton-pump inhibitor which attenuates lysosomal acidification, results in similar blocks in autophagosome-lysosome fusion as LSDs, suggesting that there may be ways that defective lysosomal function feed back to inhibit autophagosome-lysosome fusion.
Importantly, we found that the ubiquitin-proteasome degradation is not impaired in our LSD mouse models. Proteasome dysfunction may lead to the accumulation of ubiquitinated inclusions (35) and has been associated to neurodegenerative diseases (36 -38) . The finding that UPS is functional in our LSD models allows us to conclude that the block of autophagy pathway is the only mechanism accounting for the accumulation of ubiquitinated proteins which are the putative mediators of cell death in LSDs. Interestingly, a recent work from Pandey et al. (39) showed that autophagy and proteasome are compensatory interacting systems, and pointed to the role of autophagy in rescuing protein degradation deficiency due to the proteasome impairment. This finding raises the possibility to exploit new therapeutic approaches for LSDs based on pharmacological induction of proteasome function in order to compensate for autophagy deficiency.
Our model defines LSDs as 'autophagy disorders', resembling more common neurodegenerative diseases such as Alzheimer (AD), Parkinson (PD) and Huntington (HD) diseases. While there are major differences in the initial steps involved in all these diseases (i.e. impaired degradation of polyubiquitinated proteins in LSDs versus expression of aggregate-prone proteins in AD, PD and HD), our data suggest that they may share common mechanisms suggesting the possibility of overlapping therapeutic strategies.
METHODS
Generation of MEFs and ELMs
MEFs were isolated by trypsinization of littermate embryos isolated at E14 and grown in DMEM supplemented with 20% FBS and penicillin/streptomycin. Fetal liver cells were isolated from E14.5 embryos by mechanical homogenization and filtering through a 40 mm cell-strained. The cells were resuspended in DMEM plus 10% fetal bovine serum and allowed to attach to plastic. Adherent macrophages (obtained by washing wells in DMEM to remove non-adherent cells) were cultured in macrophage medium (PAA) and repurified by immune-separation using CD11b-coating magnetic beads 
Transfections and drug treatments
Sub-confluent cells (MEFs or ELMs) were transfected using lipofectamine TM 2000 (Invitrogen) according manufacturer's protocols. For co-localization experiments in normal serum conditions, sub-confluent MEFs were co-transfected with 0.5 mg lgp120-GFP and 1 mg mCherry-LC3mCherry-LC3 and cultured in full medium for 24 h. For drug treatments, cells were treated for 14 h with 0.2 mg/ml rapamycin (Sigma), 200 nM bafilomycin A1 (Upstate).
Cloning of mCherry-hLC3B construct
Human LC3B was subcloned from pGEX-6P-1 into pcDNA3 (Invitrogen) using BamHI and EcoRI (both NEB). mCherry pRSET-B was amplified by PCR with the following primers: 5'-TA CCG AGC TCG GTA CCC GCC ACC AT-3' and 3'-G CTG TAC AAG CAA GGA TCC TGC-5'. The resulting fragments were purified, digested with KpnI and EcoRI (both NEB) and sub-cloned in frame into the 5' end of hLC3B pcDNA3.
Antibodies
Primary antibodies were: rabbit polyclonal anti-LC3 (Novus Biological), rat monoclonal anti-mouse LAMP1 (Developmental Studies Hybridoma Bank, Iowa), rabbit polyclonal anti-ubiquitin (DakoCytomation), mouse monoclonal antiNeuN (Chemicon), mouse monoclonal P62/SQSTM1 (BD), rabbit polyclonal anti-tubulin (Cell signaling), rabbit polyclonal anti-actin (Sigma) and mouse monoclonal anti-COX4 (Clontech). Secondary antibodies were: goat anti-rabbit or anti-rat conjugated to Alexa Fluor 488 or 594 (Molecular Probes, Eugene, OR, USA). HRP-conjugated anti-mouse or anti-rabbit IgG (Amersham); biotinylated donkey anti-rabbit (Jackson ImmunoReasearch). (4 h). Cells were then stained with 40 nM DiOC6 and 1 mg/ml propidium iodine. DYm was measured by flow cytometry. Propidium iodine was used as counterstain. All experiments were performed in triplicate and analyzed using Stat-View software and ANOVA test. Results were considered significant if P , 0.05.
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Western blot
Cells were lysed in cold lysis buffer (20 mM Tris -HCl, pH 7.4,150 mM NaCl, 1% TritonX-100) in the presence of protease inhibitors (Roche Diagnostics) for 30 min on ice. Brain tissue samples were homogenized in sucrose buffer, centrifuged and resulting supernatants lysed in TritonX-100. Proteins were transferred onto nitrocellulose membrane (Amersham Pharmacia Biotech). Primary and (HRP)-conjugated antibodies were diluted in 5% milk. Bands were visualized using the ECL detection reagent (Pierce). Proteins were quantified by the Bradford method.
GFP analysis and immuno-staining
Cells were grown on coverslips and fixed in PBS pH 7.4 4% paraformaldehyde (GFP analysis) for 20 min. Tissues were fixed overnight in PBS pH 7.4 4% paraformaldehyde and were embedded in optimal cutting temperature compound (Tissue Tek). Cryostat sections were cut at 10 mM. For immunofluorescence analysis, cells/tissues were permeabilized and incubated with appropriate primary and secondary antibodies (diluted in PBSþ1% FBS). Immuno-histochemistry was performed using Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) according to standard protocols. Cells/tissue slides were mounted and cover-slipped in glycerol/DAPI and viewed on an epi-fluorescent microscope or counterstained with hematoxylin and viewed on a light microscope (immuno-histochemical analysis).
Confocal microscopy
For co-localization analysis in normal serum conditions, cover slips were blinded and 20 cells per cell line per experiment were imaged on a Zeiss Axiovert 200 M microscope with a LSM 510 confocal attachment using a Â63 1.4 NA Plan Apochromat oil-immersion lens. Laser lines at 488 nm (lgp120-GFP) and 543 nm (mCherry-LC3) were used. The detector pinholes were set to give a 0.9 mm optical slice. Acquisition was performed using Zeiss LSM 510 software. These cells were then analysed in Zeiss LSM Image Browser 3.5 as follows: first, only mCherry-LC3þ vesicles were counted and marked, by switching off the GFP-channel. Then, the GFP-channel was switched back on and the number of co-localized vesicles was counted. From these two values, the fraction of co-localized vesicles was then determined. (Improvision). Pearson's correlation was used as a value of co-localization between autophagosomes and lysosomes.
Mitochondrial membrane potential measurements
PBS-washed 1Â10 6 cells were incubated in 40 nM DiOC 6 (Sigma-Aldrich) and 1 mg/ml PI (Sigma-Aldrich) for 15 min at 378C. After washing, cells were suspended in 1 ml PBS (pH 7.4) and were subsequently analyzed using flow cytometry. For the DiOC 6 -stained samples, PI-negative cells were excluded of the analysis. Normal and starved MSD and wildtype MEFs were analyzed at the same passage and treated in the same way. At least 10 000 cells were analyzed for each sample. The experiments were performed at least in triplicate, and all statistical analyses were performed using Stat-View 5.0 (Statsoft, USA).
Electron microscopy analysis
MEFs were fixed at room temperature, in 2.5% glutaraldehyde (Polysciences, Inc., Warrington, PA, USA), 0.1 M sodium cacodylate -HCl buffer, pH 7.3, for 10 min, scraped off the dish, pelletted by centrifugation and postfixed in 1% OsO4 (Polyscience) in the same buffer, for 20 min. After en bloc staining with 1% uranyl acetate for 1 h and ethanol dehydration, cells were embedded in LX112 (Polyscience). Tissue preparations were performed as previously described (26) . Grey-silver sections were visualized using FEICM10 and Tecnai12G2 microscopes. Morphometry assessment of both number and size of the autophagosomes in MSD and wild-type MEFs was performed by the point intersection method.
Assay of proteasome activity
Chymotrypsin-like activity of 20S proteasomes was measured on brain homogenates using Suc-LLVY-AMC as substrate (20S proteasome activity assay kit; Chemicon).
Data analysis
Data were analyzed by one-way ANOVA (analysis of variance). A P-value ,0.05 was considered to be statistically significant. Odds ratios for co-localization LAMP1-LC3 were determined by unconditional logistical regression analysis, using the general log-linear analysis option of SPSS 9 software (SPSS, Chicago).
